海正药业引进首个创新小分子偶联药

Core Viewpoint - Haizheng Pharmaceutical has announced a collaboration with Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd. to introduce the targeted small molecule conjugate drug HSE-001 (AST-3424) in specific regions, marking its first potential First-in-Class (FIC) small molecule conjugate drug [1] Group 1 - Haizheng Pharmaceutical will acquire the rights to HSE-001 (AST-3424) across mainland China, Hong Kong, and Macau [1] - The collaboration includes the development of additional new drugs based on the AKR1C3 enzyme-activated targeted small molecule conjugate (SMDC) technology platform [1]